747
Views
7
CrossRef citations to date
0
Altmetric
Review Article

Liposomal bupivacaine – New trends in Anesthesia and Intensive Care UnitsFootnote

, , , , , , , & show all
Pages 89-95 | Received 15 Jun 2014, Accepted 15 Dec 2014, Published online: 17 May 2019

Figures & data

Figure 1 Properties of liposomal nanovesicles.
Figure 2 PEGylated lipid bilayer [Citation15].
Figure 3 Liposomal bufalin functionalized with citrus pectin [Citation11].
Figure 4 In vitro release kinetic profiles of bufalin from liposomal bufalin (BFL), liposomal bufalin functionalized with pectin citrus (CPL) compared to freely soluble bufalin [Citation11].
Figure 5 Bupivacaine – chemical structure.
Figure 6 Cumulative release of bupivacaine form Exparel™ and release of unencapsulated 1.31% w/v and 0.5% w/v bupivacaine HCl [Citation57].
Figure 7 Sciatic nerve samples harvested from rats 4 day after injection with either Exparel™ (A), bupivacaine HCl 0.5% w/v (B), bupivacaine HCl 1.31% w/v (C) or uninjected sciatic nerve (D) [Citation57].
Figure 8 Plasma bupivacaine concentration after administration of DepoFoam bupivacaine or bupivacaine HCl to patients undergoing total knee arthroplasty [Citation62].
Figure 9 Mean blinded care provider’s satisfaction with analgesia (rating scale: 0 = completely unsatisfied patients analgesia and 10 = completely satisfied patients analgesia) [Citation62].